A new clinical trial involving vosoritide was listed as recruiting on July 24, 2026. The study, registered as NCT07441876, is titled "Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia."
The trial is in Phase 2/3 and its current status is recruiting, according to the ClinicalTrials.gov listing. The study compares BMN 333 against vosoritide, an already approved treatment, in children with achondroplasia.
No results or outcome data have been posted for this trial at this time. The listing reflects only the trial's design, phase, and recruitment status as of the date noted. No efficacy or safety conclusions can be drawn from a recruiting status alone.
Further details on eligibility, trial design, and enrollment can be found through the official ClinicalTrials.gov registration for this study. Updates to trial status, including any future results, would be reflected in subsequent registry updates.
Readers interested in background on vosoritide, including its approved use, can consult the compound overview for additional context.